What To Know: Lipella completed the Phase 2a clinical trial evaluating the safety and efficacy of LP-10 for hemorrhagic cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments.

All subjects tolerated LP-10 instillations and completed the study without report of product related serious adverse events. LP-10 pharmacokinetic analysis demonstrated short duration of systemic uptake. Responder analysis noted complete response in three subjects, partial response in seven subjects and no response in three subjects.

Kaufman is set to present these results at Biotech Showcase 2023 Wednesday evening at 5 p.m. ET.

Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications.

See Also: Best Biotech Stocks Right Now

LIPO Price Action: Lipella shares are up 65.4% at $5.15 at time of publication, according to Benzinga Pro.

Photo: Konstantin Kolosov from Pixabay.